Academic Medical Center (AMC)
Meibergdreef 9
1105 AZ Amsterdam
Website Academic Medical Center
E-mail Amsterdam Medical Center
T +31 (0)20 566 50 56
F +31 (0)20 566 91 68

Employees in Amsterdam: 6,500
Employees in R&D: 1,400
Year of foundation: 1983

Company Profile

Science and Technologies or Services

AMC is active in the following research fields:

• Cardiovascular Diseases
• Gastr-intestinal diseases
• Immunity and Infections
• Metabolic Disorders
• Neurologic and Psychiatric Disorders
• Oncology
• Public Health and Epidemiology

AMC also offers advanced facilities and highly qualified personnel in the areas of gene and cell therapies, viral vector production, genomics, proteomics, metabolomics, bioinformatics, imaging, and animal models.

Alliances

AMC spin-offs:

• AIMM Therapeutics
• AMCAS
• Amsterdam Molecular Therapeutics (AMT)
• Arthrogen
• Hep-Art Medical Devices
• IATEC
• Macrozyme
• MicroVision Medical
• Primagen
• Valletta Health

Keywords

• Academic hospital
• Medical research
• License opportunities
• Spin-off companies
  

Arthrogen B.V.
Meibergdreef 45
1105 BA Amsterdam
Website Arthrogen B.V.
E-mail Arthrogen B.V.
T +31 (0)20 566 26 48
F +31 (0)20 566 91 68

Employees in Amsterdam: 10
Employees in R&D: 9
Year of foundation: 2005

Company Profile

Arthrogen was founded in 2005 as a joint venture of the Academic Medical Center (AMC, Amsterdam, The Netherlands) and the Dubai Bones and Joints Hospital for the clinical and commercial development of an innovative gene therapy approach, developed by researchers of the AMC, as a cure for rheumatoid arthritis locally in the joints. The lead compound will enter phase-I trials in two years.

Science and Technologies or Services

Development of local gene therapy targeting TNF might provide a novel method to treat isolated arthritis activity. This could lead to the development of novel therapeutic strategies targeting primarily the site of inflammation and prevent joint destruction. The gene delivery approach, in addition to other therapeutics, may ultimately provide a more comprehensive treatment for the management of RA. Obviously, achievement of this goal will have a substantial beneficial effect on the RA patient and ultimately on society. Arthrogen aims to develop several innovative medical strategies using gene therapy for local treatment of RA, using several types of cytokines.

Alliances

• Dubai Bones and Joints Center
• Academisch Medisch Centrum Amsterdam
• Galapagos BV
• Agendia BV

Keywords

• Rheumatoid arthritis
• Gene therapy
• Local administration
• Cytokines
  
  
  

Piet Heinkade 183
1019 HC Amsterdam
Website
E-mail
T +31 (0)88 650 6500
F +31 (0)88 650 6555

Employees: 3
Employees in R&D: 0
Year of foundation: 2011

Company Profile

We focus entirely on the life sciences, together we have over 20 years of experience in the life science sector both as attorney at law and as in-house counsel.

Keywords

• law
• legal services
• coaching of high tech and life sciences start-up and spin-out companies

Zernikedreef 11
2333 CK Leiden
Website
E-mail
T +31 (0)71 518 8743
F +31 (0)71 518 8415

Employees: 6
Employees in R&D: 0
Year of foundation: 2007

Company Profile

CBD is a non-profit organization staffed by a small, dedicated group of lecturers affiliated to the Faculty of Technology in the University of Applied Sciences Leiden (Hogeschool Leiden). We possess a track record in successful postgraduate education of technical lab personnel, spanning over 20 years. Our main focus is to strengthen and modernize the theoretical and practical knowledge base of technical personnel involved in laboratory work in health care, pharmaceutical, industrial and forensic settings, thereby providing a secure basis for quality improvement. We also provide consultancy services for clients seeking to optimize lab tests and boost their quality assurance procedures.
Organisations who chose CBD for their schooling and training needs include VUmc, Crucell, Philips Healthcare Incubator, UMC Groningen, Naktuinbouw, Radboud University Medical Center, Vitens, Erasmus Medical Center and Heineken.

Science and Technologies or Services

CBD is active in the following areas of life science training and consultancy:

• Molecular biology/molecular diagnostics
• Microbiology/infectious diseases
• Immunology and immunochemistry
• Clinical chemistry and hematology
• Histology/pathology
• Agriculture/horticulture

CBD offers

• training courses for groups or individuals (at the University of Applied Sciences Leiden)
• incompany training trajectories, in which the course content is tailored to fit the schooling and quality improvement needs of the client
• consultancy services
• organization of conferences.

Alliances

• Toplab @ Hogeschool Leiden
• Naktuinbouw
• Boerhaave Nascholing, LUMC
• Symbiant

Keywords

• University of Applied Sciences Leiden
• life sciences
• postgraduate professional education
• in company training
• consultancy
• molecular biology/ molecular diagnostics
• microbiology/ infectious diseases
• immunology and immunochemistry
• clinical chemistry and hematology
• histology / pathology
• agriculture / horticulture

Clinical Reach Drug Development b.v.
Zoeterwoudseweg 74
2321 GP Leiden
Website Clinical Reach
E-mail Clinical Reach
T +31 (0)71 531 18 52

Employees in Amsterdam: 1
Employees in R&D: 1
Year of foundation: 2009 

Company Profile

Clinical Reach is an independent company that aims to be a partner in your development team, from the strategic level down to the level of hands-on support in the execution of individual studies.

Company Profile

We join you in your goal to develop a product that meets regulatory expectations and that will be commercially successful. Pending your needs, we support you in your efforts to:

• Define the target product profile. 
•  Define the development plan that brings you to that target. 
•  Seek key opinion leader and regulatory authority challenge of the target product profile and development plan. 
•  Design the individual studies in your development plan. 
•  Identify the appropriate contract research organization to execute your studies, and work with this external partner on a day-to-day basis until the study has been reported. 
•  Present your plans and data to external parties, including investors, potential licensing partners and regulatory agencies.

Alliances

We are informally associated with various expert companies and individual experts providing services complementary to those of Clinical Reach, including:

• Regulatory services. 
•  Pharmaceutical development and clinical trial material production, packaging and labeling.
• Clinical study execution and management services. 
•  Recording and reporting of electronic patient-reported outcome (ePRO) data. 
•  Bioanalytical services, including biomarker assays and immunogenicity assessments. 
•  Pharmacokinetic and –dynamic data analysis. 
•  Modeling and simulation from clinical trial design to kinetic and dynamic data. 
•  Data management and statistics. 
•  Medical writing.

Keywords

• Target product profile
• drug development
• regulatory challenge
• key opinion leader challenge
• study design and execution
  

Clinquest Group
Science Park 406
1098 XH Amsterdam
Website Clinquest Group
T +31 (0)20 751 20 41
F +31 (0)20 751 20 40

Employees in Amsterdam: 2
Employees in R&D: 1
Year of foundation: 2004

Company Profile

The Clinquest Group is a trusted Healthcare Product Development Organization (PDO), which offers comprehensive product development services to the bio-pharmaceutical, medical device, diagnostics and medical data industries worldwide. Clinquest provides high-level strategic consulting as well as hands-on implementation services. Clinquest is recognized as a leader in the development of new, breakthrough technologies, first-in-man clinical trials and complex clinical studies. The Clinquest Group operates through three wholly-owned subsidiaries: Clinquest Inc., Clinquest Europe and Clinquest Pharmaceutical Innovations.
Clinquest Pharmaceutical Innovations offers innovative risk sharing partnerships to selected clients, connecting the company's development resources and expertise with the clients' discovery efforts. Clinquest Pharmaceutical Innovations is based in Amsterdam, the Netherlands.
The company is headquartered in Amsterdam, the Netherlands, and has offices in the USA and Singapore.

Science and Technologies or Services

Expertise throughout the pipeline:
Strategic product development planning, Medical affairs, Preclinical R&D, Regulatory, Manufacturing, Clinical, Pharmacovigilance, Due diligence services

Alliances

We have published alliances with TNO, Galapagos, Enceladus, Utrecht University as well as a whole range of small, medium and large clients in the pharma, biotech and medical device industry.

DC Prime B.V.
De Boelelaan 1085
1081 HV Amsterdam
Website DC Prime B.V.
E-mail DC Prime B.V.
T +31 (0)6 5517 21 58
F +31 (0)20 598 99 04

Employees in Amsterdam: 9
Employees in R&D: 9
Year of foundation: 2005

Company Profile

Science and Technologies or Services

In one arm of its technology base, DCPrime develops sustainable DC lines that can be clinically applied as off-the-shelf DC vaccines. These can be loaded with the desired tumor antigens, but also with viral antigens or antigens for which tolerance is desirable. Also other genes of interest can be introduced into these DC lines without harming their antigen presentation potential, to introduce desirable modulations.
The first DC line, DCOne, is currently being prepared for entering clinical testing, and with several external partners. Scale-up procedures are being developed, and QA/QC compliant dossiers are being built on product specifications, production parameters, harvesting and storage conditions, quality assays, and reproducibility of all processes.
In the second arm of its technology base, DCPrime is performing pre-clinical validation of innovative DC targeting tools that can be directly applied to skin. The technological basis for these products will be prepared for strategic collaborations with co-development partners.

Alliances

DCPrime BV works together with the VU medical center, and with many life sciences companies and CRO’s in Europe.

Keywords

• Cancer
• Immunotherapy
• Autoimmunity
• Dendritic cells
  
  
  

DC4U B.V.
Van der Boechorststraat 7
1081 BT Amsterdam
E-mail DC4U B.V.
T +31 (0)20 444 80 84
F +31 (0)20 444 80 81

Year of foundation: 2006

Company Profile

Science and Technologies or Services

Recently, glycomics research has yielded potential leads that may provide innovative solutions for the treatment of cancer. Glycomics is a new biomedical discipline that investigates how sugar modification of macromolecules (glycosylation) affects their biological and pathological function. Recent exciting discoveries in this field, in which Prof. Dr. Y. van Kooyk has a world-leading role, are further explored. DC4U B.V. strongly believes that liposomes containing highly specific APC-targeting signals using glycans provide the answer in the search for a new vaccine to cure colon cancer. The fact that certain glycans can target two different APC subsets allows us for the first time to design a vaccine that targets both subsets that have strong immune-modulating capacity.

Alliances

• Drug Discovery Factory B.V.
• VU Medical Center Amsterdam
• Octoplus Technologies B.V.
• Utrecht University
• Technical University Munchen

Keywords

• Cancer
• Therapeutics
• Vaccines
• Immunotherapy
• Autoimmunity
• Dendritic Cells
• Drug Discovery

Drug Discovery Factory BV
Albrechtlaan 14a
1404 AK Bussum
Website Drug Discovery Factory B.V.
E-mail Drug Discovery Factory B.V.
T +31 (0)35 695 40 50

Employees in Amsterdam: 14
Employees in R&D: 10
Year of foundation: 2003

Company profile

Currently the DDF group consists of 12 companies in the life sciences Using a hands-on approach and dedication to meet customer demands we aim to create value for our clients and other stakeholders. Peter Schoevers and Henk Viëtor, the founders of DDF, have established themselves as two of the leading Life Sciences entrepreneurs behind successful companies such as Recharge, DCPrime, Skyline Diagnostics, Dynomics and Julius Clinical Research.

Science and Technologies or Services

Selecting
DDF selects the most attractive research projects at leading University Medical Center and other research institutions.

Financing
DDF provides and/or organizes funding and grants.

Managing
DDF monitors the projects, files patents, finds partners, provides (project) management.

Commercialising
DDF markets and sells projects, products and services.

Consulting
The team of 14 employees of DDF undertakes management activities, consultancy activities, IP management and financial administration activities.

Alliances

We have a dedicated network of partners to realize research and development projects and work closely with academic hospitals, regulatory authorities and local and national governments.

Keywords

• Drug development;
• University;
• Intellectual property;
• Consultancy;
• Entrepreneurship;
• Commercialisation.

Schutteheiweg 37
6343AG Klimmen
Website
e-mail
T +31 (0)6 5460 7087

Employees: 1
Year of foundation: 2008

Company Profile

Science and Technologies or Services

Alliances

Keywords

Fornix BioSciences N.V.
Vijzelweg 11
8243 PM  Lelystad
Website Fornix BioSciences N.V.
E-mail Fornix BioSciences N.V.
T +31 (0)320 26 79 00
F +31 (0)320 26 77 91

Employees in Amsterdam: 200
Year of foundation: 1999

Company Profile

Fornix BioSciences N.V. is a listed company (Euronext Amsterdam: AFORBI) with business locations in Lelystad and Beuningen. The concern, with 200 employees, has a large number of clients in the Netherlands and other European countries. The activities are organised into three divisions, the Allergy division, the division Medical Aids and the Trading division. The concern intends to achieve a prominent position in the niches in which the concern operates. Fornix BioSciences also intends to make a contribution to the improvement of the health and quality of life of people.

Keywords

• Listed company
• Immunotherapy
• Allergy
• Medical aids/nursing disposables
• Health

Genmab B.V.
Yalelaan 60
3508 AD Utrecht
Website Genmab B.V.
T +31 (0)30 212 31 23
F +31 (0)30 212 31 10

Employees in Amsterdam: 130
Employees in R&D: 130
Year of foundation: 2001

Company Profile

Science and Technologies or Services

Genmab uses a combination of innovative technology platforms in multidisciplinary teams of biologists, biochemists and MD's. Antibodies, one of the body’s most important natural defenses, are proteins that seek out, recognize and bind to disease targets. A specific antibody directs the immune system to a particular target like a key fitting into a lock. It is this specificity that makes antibodies potentially useful in various therapeutic applications. Our skilled pre-clinical team, located in Utrecht, ensures that the best possible antibody candidate is selected to become a potential product. A panel of antibodies is generated and these antibodies are put through a rigorous series of laboratory functional assays designed to identify characteristics of the best therapeutic product.

Alliances

Keywords

• Genmab;
• Biotech;
• Human antibodies;
• Monoclonal antibodies;
• Drug discovery;
• Drug development;
• Pre-clinical;
• Oncology;
• Inflammatory diseases;
• Infectious diseases.

Genzyme Nederland
Gooimeer 10
1411 DD Naarden
Website Genzyme Nederland
E-mail Genzyme Nederland
Promotion video Genzyme Nederland
T +31 (0)35 699 86 00
F +31 (0)35 699 86 21

Employees in Amsterdam: 415
Employees in R&D: 150
Year of foundation: 1991

Company Profile

Science and Technologies or Services

Genzyme’s research and development efforts are focused on the areas of medicine where it markets commercial products. The company also conducts research in cardiovascular disease and other areas of unmet medical need. In 2006, the company invested approximately $565 million in this work, or about 18 percent of its revenues. Genzyme identifies unmet medical needs and its large team of scientists and researchers uses a broad range of scientific approaches and technologies to meet those needs. The company is a leader in novel areas such as cell and gene therapies and biomaterials. Genzyme also partners with other companies to develop new products and supports research conducted by top academic and independent medical science centers.

Alliances

Genzyme has many different alliances with companies and research groups around the world. In the Netherlands Genzyme is collaborating with Macrozyme BV in the area of diabetes and scientific and clinical projects are ongoing with researchers in several academic centers, including the AMC.

Keywords

• Orphan diseases
• Renal disease
• Oncology
• Transplant
• Orthopedics
• Familial Hypercholesterolemia
  
  

Greenberg Traurig LLP
Strawinkskylaan 3127
1077 ZX Amsterdam
Website
E-mail
T +31 20 301 7436
F +31 20 301 7350

Employees: 100
Employees in R&D: 60
Year of foundation: 2003

Company Profile

Greenberg Traurig is a law firm of 1800 lawyers in more than 30 locations focused on helping businesses navigate change in every way. Through its offices in the US, Europe and Asia it has a global reach yet local footprint.

Science and Technologies or Services

GT provides world-class and worldwide industry-oriented life sciences legal services in all areas of law, including IP, licensing, M&A, regulatory compliance, litigation, etc.

Alliances

Through its alliance partners GT can provide legal services in markets where it is not established itself, enabling GT to provide legal services in every country in the world.

Keywords

• Legal
• Regulatory
• M&A
• Contracts
• Litigation

Company Profile

The company spun-out of VU University Amsterdam in 2009 and is based on over 30 years of GPCR research. At present the company works in close collaboration with the academic group and has obtained all intellectual property rights to its GPCR research programs.

Current in-house discovery is comprised of a selective histamine H3R antagonist and histamine H4R antagonist program. In addition to the development of selective antagonists, a series of compounds is being developed with a mixed histaminergic profile that combines histamine H1R and histamine H4R antagonism in a single non-imidazole molecule.

Science and Technologies or Services

Griffin Discoveries offers comprehensive in vitro profiling of compounds that allows for a better understanding of observed compound behavior in vivo. Compound profiles for ligand binding and receptor activation can be generated for all histamine receptors of human, mouse and rat. In addition, profiles can be generated for monkey, dog and guinea-pig histamine receptors upon special request.

Alliances

• VU University Amsterdam

Keywords

• Drug Discovery
• Histamine ligands
• Histamine receptor & other screening assays